Fractyl Health

Transformative Metabolic Therapies

Clinical Studies

Pursuing therapies that target the root cause of obesity and type 2 diabetes.

Obesity

REMAIN-1

Clinical study in patients who have lost at least 15% total body weight on GLP-1 drug therapy and wish to discontinue their GLA-1 drug without weight regain.

Learn More about REMAIN-1

Status

Recruiting

Eligibility Criteria

Adults aged 21-70 with BMI ≥30 kg/m2 (obesity) and ≤45 kg/m2 prior to tirzepatide therapy; history of at least 1 self-reported unsuccessful dietary effort to lose weight; able to walk at least 400 yards and climb a flight of stairs

Type 2 diabetes

REVITALIZE-1

Pivotal clinical study in patients with inadequately controlled type 2 diabetes despite the use of at least 1 glucose lowering agent (GLA).

Learn More about REVITALIZE-1

Status

Recruiting

Eligibility Criteria

Adults diagnosed with type 2 diabetes aged 21-70; HbA1c between 7.5-10%; BMI 24-40; currently on at least one GLA

Erase Task Force.

Advancing research on the role of the gut in metabolic disease

Led by world-renowned experts in metabolic disease, the Erase Task Force shares Fractyl Health’s mission to build evidence to understand and ultimately eradicate metabolic disease.

The Erase Task Force builds on decades of discovery that have clearly identified the critical role of the gut as a regulator of metabolic disease. The signaling mechanisms between the gut and the rest of the body are numerous and not yet fully understood. The TaskForce is charged with advancing research on the role of the gut in metabolic disease to catalyze future discoveries that may inform how obesity and diabetes can be better understood and ultimately erased.

This initiative, funded by Fractyl, is meant to spur the kind of innovative thinking and fundamental breakthroughs that will point the way toward a world without obesity and type 2 diabetes.